Trending Topic

Illustration of the thought processes in the brain
13 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The prevalence of unruptured intracranial aneurysms (IAs) is approximately 3% of the population, with incidence on the rise due to the increased utilization of neuro-imaging for diverse objectives.1,2 The average risk of rupture for unruptured IA is estimated to vary from 0.3% to exceeding 15% per 5 years.3 Ruptured IA is the primary aetiology of […]

What about treatment for progressive forms of MS? Q14

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 7th 2012

The MS Trust has asked Professor David Bates, Consultant Neurologist at University of Newcastle-upon-Tyne NHS Hospitals Foundation Trust to answer some of the most challenging questions people with MS ask about disease modifying drugs.


The MS Trust has asked Professor David Bates, Consultant Neurologist at University of Newcastle-upon-Tyne NHS Hospitals Foundation Trust to answer some of the most challenging questions people with MS ask about disease modifying drugs.

With newer, more potent MS drug therapies on the horizon, treatment decisions for both people with MS and their health professionals are about to become much more complex. It is more important than ever that people with MS have the information they need to make informed decisions in partnership with their health professionals. Health professionals need to communicate effectively with people with MS in order to quantify the risks and benefits of the various treatment options.

Need to know more? Why not ask Prof David Bates and Vicki Matthews questions from February 2011 to end of March 2011 by visiting the MS Trust Webcast pages – http://www.mstrust.org.uk/information/webcast/questions/q14_primary_progressi…

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup